Cisatracurium besylate

sc-357315

Material Safety Data Sheet

Hazard Alert Code Key: EXTREME HIGH MODERATE LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Cisatracurium besylate

STATEMENT OF HAZARDOUS NATURE

NFPA

SUPPLIER
Company: Santa Cruz Biotechnology, Inc.
2145 Delaware Ave
Santa Cruz, CA 95060
Telephone: 800.457.3801 or 831.457.3800
Emergency Tel: CHEMWATCH: From within the US and Canada: 877-715-9305
Emergency Tel: From outside the US and Canada: +800 2436 2255
(1-800-CHEMCALL) or call +613 9573 3112

PRODUCT USE
Neuromuscular blocking agent used as intermediate-duration, non-depolarising, skeletal muscle relaxant. Administered by intravenous injection. Used as an adjunct to general anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. WARNINGS: Should be used only by those skilled in the management of artificial respiration and only when facilities are instantly available for endotracheal intubation and for providing adequate ventilation of the patient, including the administration of oxygen under positive pressure and the elimination of carbon dioxide. The clinician must be prepared to assist or control respiration and anticholinesterase reversal agents should be immediately available. Cisatracurium besylate has the potential to cause histamine release and therefore there is a possibility of life threatening anaphylactic reactions. It is therefore essential that appropriate resuscitative equipment be immediately available. Do not give by intramuscular administration. The neuromuscular blocking potency of cisatracurium besylate is approximately threefold that of atracurium besylate. The time to maximum block is up to 2 minutes longer for equipotent doses of cisatracurium besylate compared to atracurium besylate. The clinically effective duration of action and rate of spontaneous recovery from equipotent doses of cisatracurium besylate and atracurium besylate are similar. Cisatricurium is one of the ten isomers of atracurium. Its active metabolites contain less laudanosine which cause hypotension, central nervous system excitation, and seizures than that of atracurium. It is considered an intermediate-acting agent in terms of duration of action.

SYNONYMS
C53H72N2O12.2C6H5O3S, [1R-[1a, 2a(1’ R*, 2’ R*)]]-2, 2’-{1, 5-pentanediylbis[oxy(3-oxo-3, 1’)-propanediyl)]bis[1-{[3, 4-dimethoxyphenyl]methyl}-1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methylisoquinolinium], dibenzenesulfonate, "2, 2’-[1, 5-pentanediylbis(oxy(3-oxo-3, 1-propanediyl))bis[1-{((3, 4-dimethoxyphenyl)methyl}-1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2, 7-dimethoxyisoquinolinium] dibenzenesulfonate", "2-(2-carboxyethyl)-1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate pentamethylene ester", "isoquinolinium, 2, 2’-(1, 5-pentanediylbis(oxy(3-oxo-3, 1’)-propanediyl)]bis[1-{[3, 4-dimethoxyphenyl]methyl}-1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate", "cis-atricurium besylate", "cisatricurium besylate", "santa cruz biotechnology", "nimbex", "muscle relaxant", "bisbenzyltetrahydroisoquinolinium agent", "quaternary ammonium compound"

Section 2 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW

RISK
Harmful to aquatic organisms.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
■ Accidental ingestion of the material may be damaging to the health of the individual.
■ Tubocurarine and its structural analogues rarely produces side-effects at levels employed during anaesthesia but in overdose may cause respiratory failure (by paralysing intercostal muscles and the diaphragm) and hypotension. Regurgitation of stomach contents may also occur as a result of relaxation of the oesophageal muscle and sphincters. May cause bronchospasm due to histamine release. Members of this family of muscle relaxant have relatively little cardiovascular activity although tachycardia has been reported.
■ Drugs which activate nicotine receptors (one type of cholinergic receptor), primarily affect the neuromuscular junction, producing, for example, fasciculations, weakness and paralysis. Activation of the receptor by cholinergic agonists initially stimulates autonomic ganglia and neuromuscular junctions, and then, in high doses, produces blockade. Acetylcholine is the major peripheral neurotransmitter.
■ d-Tubocurarine blocks the nicotinic effects in the neuromuscular junction. Cholinergic receptors are located in the parasympathetic nervous system which, when activated, inhibits the activity of most target organs.

EYE
■ Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn). Slight abrasive damage may also result. The material may produce foreign body irritation in certain individuals.

SKIN
■ The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.
■ Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED
■ The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models). Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
■ Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

CHRONIC HEALTH EFFECTS
■ Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.
There is limited evidence that, skin contact with this product is more likely to cause a sensitization reaction in some persons compared to the general population.
■ Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung. Prime symptom is breathlessness; lung shadows show on X-ray.
■ Exposure to small quantities may induce hypersensitivity reactions characterized by acute bronchospasm, hives (urticaria), deep dermal wheals (angioneurotic edema), running nose (rhinitis) and blurred vision . Anaphylactic shock and skin rash (non-thrombocytopenic purpura) may occur. An individual may be predisposed to such anti-body mediated reaction if other chemical agents have caused prior sensitization (cross-sensitivity).
■ The benzylisoquinoline alkaloids (BIAs) are a complex and diverse group of natural products consisting of more than 2500 known structures. The general role of alkaloids in the chemical defense of plants against herbivores and pathogens suggests that BIAs contribute to the reproductive fitness of plants with the ability to produce these compounds.
■ Certain benzylisoquinoline compounds used in neuromuscular blockade have a tendency to release histamine, particularly at higher doses.
■ Although atracurium besylate is a less potent histamine releaser than d-tubocurarine, in common with most neuromuscular blocking agents...
the potential exists for histamine release in susceptible patients. Adverse reactions include skin flushing, transient hypotension, hypertension, tachycardia, bradycardia, bronchospasm and anaphylactoid reactions.

### Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>NAME</th>
<th>CAS RN</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>cisatracurium besylate</td>
<td>96946-42-8</td>
<td>&gt;98</td>
</tr>
</tbody>
</table>

### Section 4 - FIRST AID MEASURES

**SWALLOWED**
- If swallowed do NOT induce vomiting.
- If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.
- Observe the patient carefully.
- Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious.
- Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink.
- Seek medical advice.

**EYE**
- If this product comes in contact with the eyes:
  - Wash out immediately with fresh running water.
  - Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
  - If pain persists or recurs seek medical attention.
  - Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.

**SKIN**
- If skin contact occurs:
  - Immediately remove all contaminated clothing, including footwear.
  - Flush skin and hair with running water (and soap if available).
  - Seek medical attention in event of irritation.

**INHALED**
- If fumes or combustion products are inhaled remove from contaminated area.
- Other measures are usually unnecessary.

**NOTES TO PHYSICIAN**

Treatment of overdose or intoxication by tubocurarine and its structural analogues:
- In respiratory failure, respiration should be assisted.
- Neostigmine methylsulfate should be given intravenously in a dose of 2 to 3 mg over 60 secs with 0.6 to 1.2 mg of atropine sulfate.
- Additional neostigmine may be given but a total dose of 5 mg should not be exceeded.


For neuromuscular blocking agents:
- Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia. Neuromuscular blocking agents may have a profound effect in patients with neuromuscular diseases (e.g., myasthenia gravis and the myasthenic syndrome). In these and other conditions in which prolonged neuromuscular block is a possibility (e.g., carcinomatosis), ensure a peripheral nerve stimulator is available.
- The primary treatment is maintenance of a patent airway and controlled ventilation until recovery of normal neuromuscular function is assured. Once evidence of recovery from neuromuscular block is observed, further recovery may be facilitated by administration of an anticholinesterase agent (e.g., neostigmine, edrophonium) in conjunction with an appropriate anticholinergic agent (see Antagonism of Neuromuscular Block subsection below).
- Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia. The primary treatment is maintenance of a patent airway and controlled ventilation until recovery of normal neuromuscular function is assured. Once recovery from neuromuscular block begins, further recovery may be facilitated by administration of an anticholinesterase agent (e.g., neostigmine, edrophonium) in conjunction with an appropriate anticholinergic agent such as atropine.
- The possibility of iatrogenic overdosage can be minimised by carefully monitoring muscle twitch response to peripheral nerve stimulation. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension. If cardiovascular support is necessary, this should include proper positioning, fluid administration, and the use of vasopressor agents if necessary. A longer duration of neuromuscular blockade may result from overdosage and a peripheral nerve stimulator should be used to monitor recovery.
- Antagonism of Neuromuscular Block: Antagonists (such as neostigmine and edrophonium) should not be administered when complete neuromuscular block is evident or suspected. The use of a peripheral nerve stimulator to evaluate recovery and antagonism of neuromuscular block is recommended.
- Patients administered antagonists should be evaluated for adequate clinical evidence of antagonism, e.g., 5-second head lift and grip strength. Ventilation must be supported until no longer required.
- Antagonism may be delayed in the presence of debilitation, carcinomatosis, and the concomitant use of certain broad spectrum antibiotics, or anesthetic agents and other drugs which enhance neuromuscular block or separately cause respiratory depression. Under
such circumstances the management is the same as that of prolonged neuromuscular block.

- Patients with burns have been shown to develop resistance to nondepolarizing neuromuscular blocking agents, including atracurium. The extent of altered response depends upon the size of the burn and the time elapsed since the burn injury.
- Patients with hemiparesis or paraparesis also may demonstrate resistance to nondepolarizing muscle relaxants in the affected limbs. To avoid inaccurate dosing, neuromuscular monitoring should be performed on a non-paretic limb.
- Acid-base and/or serum electrolyte abnormalities may potentiate or antagonize the action of neuromuscular blocking agents.

### Section 5 - FIRE FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available</td>
</tr>
<tr>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
</tr>
</tbody>
</table>

**EXTINGUISHING MEDIA**

- Water spray or fog.
- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.

**FIRE FIGHTING**

- Alert Emergency Responders and tell them location and nature of hazard.
- Wear breathing apparatus plus protective gloves.
- Prevent, by any means available, spillage from entering drains or water course.
- Use water delivered as a fine spray to control fire and cool adjacent area.
- DO NOT approach containers suspected to be hot.
- Cool fire exposed containers with water spray from a protected location.
- If safe to do so, remove containers from path of fire.
- Equipment should be thoroughly decontaminated after use.

**GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS**

- Combustible solid which burns but propagates flame with difficulty.
- Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.
- Dry dust can be charged electrostatically by turbulence, pneumatic transport, pouring, in exhaust ducts and during transport.
- Build-up of electrostatic charge may be prevented by bonding and grounding.
- Powder handling equipment such as dust collectors, dryers and mills may require additional protection measures such as explosion venting.

Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), nitrogen oxides (NOx), sulfur oxides (SOx), other pyrolysis products typical of burning organic material.

May emit poisonous fumes.

May emit corrosive fumes.

**FIRE INCOMPATIBILITY**

- Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

**PERSONAL PROTECTION**

- Glasses: Chemical goggles.
- Gloves:
- Respirator:
- Particulate

### Section 6 - ACCIDENTAL RELEASE MEASURES

**MINOR SPILLS**

- Clean up waste regularly and abnormal spills immediately.
- Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.
- Use dry clean up procedures and avoid generating dust.
- Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- Dampen with water to prevent dusting before sweeping.
- Place in suitable containers for disposal.
MAJOR SPILLS
- Moderate hazard.
- CAUTION: Advise personnel in area.
- Alert Emergency Responders and tell them location and nature of hazard.
- Control personal contact by wearing protective clothing.
- Prevent, by any means available, spillage from entering drains or water courses.
- Recover product wherever possible.
- IF DRY: Use dry clean up procedures and avoid generating dust. Collect residues and place in sealed plastic bags or other containers for disposal. IF WET: Vacuum/shovel up and place in labelled containers for disposal.
- ALWAYS: Wash area down with large amounts of water and prevent runoff into drains.
- If contamination of drains or waterways occurs, advise emergency services.

PROTECTIVE ACTIONS FOR SPILL

WARNING
MAY DECOMPOSE EXPLOSIVELY AT HIGH TEMPERATURES.

FOOTNOTES
1 PROTECTIVE ACTION ZONE is defined as the area in which people are at risk of harmful exposure. This zone assumes that random changes in wind direction confines the vapour plume to an area within 30 degrees on either side of the predominant wind direction, resulting in a crosswind protective action distance equal to the downwind protective action distance.

2 PROTECTIVE ACTIONS should be initiated to the extent possible, beginning with those closest to the spill and working away from the site in the downwind direction. Within the protective action zone a level of vapour concentration may exist resulting in nearly all unprotected persons becoming incapacitated and unable to take protective action and/or incurring serious or irreversible health effects.

3 INITIAL ISOLATION ZONE is determined as an area, including upwind of the incident, within which a high probability of localised wind reversal may expose nearly all persons without appropriate protection to life-threatening concentrations of the material.

4 SMALL SPILLS involve a leaking package of 200 litres (55 US gallons) or less, such as a drum (jerican or box with inner containers). Larger packages leaking less than 200 litres and compressed gas leaking from a small cylinder are also considered "small spills". LARGE SPILLS involve many small leaking packages or a leaking package of greater than 200 litres, such as a cargo tank, portable tank or a "one-tonne" compressed gas cylinder.

5 Guide No guide found is taken from the US DOT emergency response guide book.

6 IERG information is derived from CANUTEC - Transport Canada.

ACUTE EXPOSURE GUIDELINE LEVELS (AEG) (in ppm)
AEG 1: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure.
AEG 2: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or an impaired ability to escape.
AEG 3: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening health effects or death.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING
- Avoid all personal contact, including inhalation.
Wear protective clothing when risk of exposure occurs.
Use in a well-ventilated area.
Prevent concentration in hollows and sumps.
DO NOT enter confined spaces until atmosphere has been checked.
DO NOT allow material to contact humans, exposed food or food utensils.
Avoid contact with incompatible materials.
When handling, DO NOT eat, drink or smoke.
Keep containers securely sealed when not in use.
Avoid physical damage to containers.
Always wash hands with soap and water after handling.
Work clothes should be laundered separately.
Launder contaminated clothing before re-use.
Use good occupational work practice.
Observe manufacturer's storing and handling recommendations.
Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.
Do NOT cut, drill, grind or weld such containers.
In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

RECOMMENDED STORAGE METHODS
- Glass container.
- Polyethylene or polypropylene container.
- Check all containers are clearly labelled and free from leaks.

STORAGE REQUIREMENTS
- Store in original containers.
- Keep containers securely sealed.
- Store in a cool, dry, well-ventilated area.
- Store away from incompatible materials and foodstuff containers.
- Protect containers against physical damage and check regularly for leaks.
- Observe manufacturer's storing and handling recommendations.

SAFE STORAGE WITH OTHER CLASSIFIED CHEMICALS

X: Must not be stored together
O: May be stored together with specific preventions
+: May be stored together

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS
The following materials had no OELs on our records
• cisatracurium besylate: CAS:96946-42-8

MATERIAL DATA
CISATRACURIUM BESYLATE:
- It is the goal of the ACGIH (and other Agencies) to recommend TLVs (or their equivalent) for all substances for which there is evidence of health effects at airborne concentrations encountered in the workplace.
At this time no TLV has been established, even though this material may produce adverse health effects (as evidenced in animal experiments or clinical experience). Airborne concentrations must be maintained as low as is practically possible and occupational exposure must be kept to a minimum.
NOTE: The ACGIH occupational exposure standard for Particles Not Otherwise Specified (P.N.O.S) does NOT apply.
Airborne particulate or vapor must be kept to levels as low as is practicably achievable given access to modern engineering controls and monitoring hardware. Biologically active compounds may produce idiosyncratic effects which are entirely unpredictable on the basis of literature searches and prior clinical experience (both recent and past).
CEL STEL: 35 μg/m3 (15 min; cf OEL GSK)

PERSONAL PROTECTION
Consult your EHS staff for recommendations

**EYE**
- When handling very small quantities of the material eye protection may not be required.

For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:
- Chemical goggles
- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59]

**HANDS/FEET**
- NOTE: The material may produce skin sensitization in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and
- dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).
- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- Contaminated gloves should be replaced.

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
- Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Protective shoe covers.
- Head covering.

Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.
- polychloroprene
- nitrile rubber
- butyl rubber
- fluorocautchouc
- polyvinyl chloride

Gloves should be examined for wear and/ or degradation constantly.

**OTHER**
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- For Emergencies: Vinyl suit

- Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.
- The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure - ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).
- Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory. These may be government mandated or vendor recommended.
- Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a
complete respiratory protection program.
* Use approved positive flow mask if significant quantities of dust becomes airborne.
* Try to avoid creating dust conditions.

### RESPIRATOR

<table>
<thead>
<tr>
<th>Protection Factor</th>
<th>Half-Face Respirator</th>
<th>Full-Face Respirator</th>
<th>Powered Air Respirator</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 x PEL</td>
<td>Air-line*</td>
<td>-</td>
<td>PAPR-P1</td>
</tr>
<tr>
<td>50 x PEL</td>
<td>Air-line**</td>
<td>P2</td>
<td>PAPR-P2</td>
</tr>
<tr>
<td>100 x PEL</td>
<td>-</td>
<td>P3</td>
<td>-</td>
</tr>
<tr>
<td>100+ x PEL</td>
<td>-</td>
<td>Air-line*</td>
<td>-</td>
</tr>
</tbody>
</table>

* - Negative pressure demand  ** - Continuous flow

Explanations of Respirator Codes:

- Class 1 low to medium absorption capacity filters.
- Class 2 medium absorption capacity filters.
- Class 3 high absorption capacity filters.

PAPR: Powered Air Purifying Respirator (positive pressure) cartridge.

- Type A for use against certain organic gases and vapors.
- Type AX for use against low boiling point organic compounds (less than 65°C).
- Type B for use against certain inorganic gases and other acid gases and vapors.
- Type E for use against sulfur dioxide and other acid gases and vapors.
- Type K for use against ammonia and organic ammonia derivatives.

Class P1 intended for use against mechanically generated particulates of sizes most commonly encountered in industry, e.g. asbestos, silica.

Class P2 intended for use against both mechanically and thermally generated particulates, e.g. metal fume.

Class P3 intended for use against all particulates containing highly toxic materials, e.g. beryllium.

The local concentration of material, quantity and conditions of use determine the type of personal protective equipment required.

Use appropriate NIOSH-certified respirator based on informed professional judgement. In conditions where no reasonable estimate of exposure can be made, assume the exposure is in a concentration IDLH and use NIOSH-certified full face pressure demand SCBA with a minimum service life of 30 minutes, or a combination full facepiece pressure demand SAR with auxiliary self-contained air supply. Respirators provided only for escape from IDLH atmospheres shall be NIOSH-certified for escape from the atmosphere in which they will be used.

### ENGINEERING CONTROLS

- Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.
- HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.
- Barrier protection or laminar flow cabinets should be considered for laboratory scale handling.
- The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated: Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated.
- Fume-hoods and other open-face containment devices are acceptable when face velocities of at least 1 m/s (200 feet/minute) are achieved.
- Partitions, barriers, and other partial containment technologies are required to prevent migration of the material to uncontrolled areas. For non-routine emergencies maximum local and general exhaust are necessary. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

#### Type of Contaminant: Air Speed:

- solvent, vapors, etc. evaporating from tank (in still air) 0.25-0.5 m/s (50-100 f/min.)
- aerosols, fumes from pouring operations, intermittent container filling, 0.5-1 m/s (100-200 f/min.)
- low speed conveyor transfers (released at low velocity into zone of active generation) 1-2.5 m/s (200-500 f/min.)
- direct spray, drum filling, conveyor loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)

Within each range the appropriate value depends on:

- Lower end of the range
- Upper end of the range

1: Room air currents minimal or favourable to capture 1: Disturbing room air currents

2: Contaminants of low toxicity or of nuisance value only. 2: Contaminants of high toxicity

3: Intermittent, low production. 3: High production, heavy use

4: Large hood or large air mass in motion 4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2.5 m/s (200-500 f/min.) for extraction of gases discharged 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

### Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

#### PHYSICAL PROPERTIES

- Solid.
Mixes with water.

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>State</td>
<td>Divided solid</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>1243.49</td>
</tr>
<tr>
<td>Melting Range (°F)</td>
<td>Not Available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Solubility in water (g/L)</td>
<td>Miscible</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not Available</td>
</tr>
<tr>
<td>pH (1% solution)</td>
<td>3.3-3.8</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>pH (as supplied)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available</td>
</tr>
<tr>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
</tr>
<tr>
<td>Relative Vapor Density (air=1)</td>
<td>&gt;1</td>
</tr>
<tr>
<td>Volatile Component (%vol)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

**APPEARANCE**
Off-white freeze dried powder; soluble in water.

---

**Section 10 - CHEMICAL STABILITY**

**CONDITIONS CONTRIBUTING TO INSTABILITY**
- Presence of incompatible materials.
- Product is considered stable.
- Hazardous polymerization will not occur.

**STORAGE INCOMPATIBILITY**
- Avoid reaction with oxidizing agents.
For incompatible materials - refer to Section 7 - Handling and Storage.

---

**Section 11 - TOXICOLOGICAL INFORMATION**

cisatracurium besylate

**TOXICITY AND IRRITATION**
- unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.
- No significant acute toxicological data identified in literature search.
Most neuromuscular blocking agents facilitate histamine release in susceptible patients. Adverse reactions include skin flushing, transient hypotension, hypertension, tachycardia, bradycardia, bronchospasm and anaphylactoid reactions.

**For cisatracurium besylate:**
Histamine release, hypersensitivity reactions including anaphylactic or anaphylactoid responses which, in rare instances, were severe. There are rare reports of wheezing, laryngospasm, bronchospasm, rash and itching following administration of cisatracurium in children. These reported adverse events were not serious and their etiology could not be established with certainty. Musculoskeletal: Prolonged neuromuscular block, inadequate neuromuscular block, muscle weakness, and myopathy.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis and fertility studies have not been performed. Cisatracurium besylate was evaluated in a battery of four short-term mutagenicity tests. It was non-mutagenic in the Ames Salmonella assay, a rat bone marrow cytogenetic assay, and an in vitro human lymphocyte cytogenetics assay. As was the case with atracurium, the mouse lymphoma assay was positive both in the presence and absence of exogenous metabolic activation (rat liver S-9). In the absence of S-9, cisatracurium besylate was positive at in vitro cisatracurium concentrations of 40 ug/mL and higher. The highest non-mutagenic concentration (30 ug/mL) and incubation time (4 hours) resulted in an AUC approximately 120 times that noted in clinical studies and approximately 8.5 times the mean peak clinical concentration noted. In the presence of S-9, cisatracurium besylate was positive at a cisatracurium concentration of 300 ug/mL but not at lower or higher concentrations.
Teratology testing in nonventilated pregnant rats treated subcutaneously with maximum subparalysing doses (4 mg/kg daily; equivalent to 8 x the human ED95 following a bolus dose of 0.2 mg/kg IV) and in ventilated rats treated intravenously with paralyzing doses of the drug at 0.5 and 1.0 mg/kg; equivalent to 10 x and 20 x the human ED95 dose, respectively, revealed no maternal or foetal toxicity or teratogenic effects.

---

**Section 12 - ECOLOGICAL INFORMATION**

Refer to data for ingredients, which follows:
CISATRACURIUM BESYLATE:
- DO NOT discharge into sewer or waterways.

**Ecotoxicity:**
Aquatic Ecotoxicity This material may be harmful to aquatic organisms.
Activated Sludge Respiration: NOEC: 320 mg/l; IC50: > 4000 mg/l, 3 Hours, Activated sludge, Nominal (not toxic to activated sludge microorganisms)
Microbial Growth Inhibition
Not toxic to the following microorganisms.
Minimum Inhibition Concentration:
300 mg/l, Azotobacter chroococcum
> 1000 mg/l, Pseudomonas fluorescens
> 1000 mg/l, Chaetomium globosum
> 1000 mg/l, Bacillus megaterium
> 1000 mg/l, Anabaena flos-aquae
> 1000 mg/l, Aspergillus clavatus
> 1000 mg/l, Penicillium canescens

Daphnia magna EC50 (48 h): 14 mg/l Daphnia magna, Nominal; NOEL: 5.6 mg/l
Harmful to daphnia

MOBILITY
Solubility: Soluble in water.
Photolysis: Chemically unstable in water when exposed to light. Aqueous photolysis may be a significant depletion mechanism.
Half-Life, Aqueous: 2.45 Days, Measured, pH 5 Buffer Solution
UV/Visible Spectrum: 280 nm
Biodegradation This material is readily biodegradable (as defined by 1993 OECD Testing Guidelines) and is not expected to persist in the environment.
Percent Degradation: 82.26 %, 28 days, Modified Sturm test.

Section 13 - DISPOSAL CONSIDERATIONS

Disposal Instructions
All waste must be handled in accordance with local, state and federal regulations.
Legislation addressing waste disposal requirements may differ by country, state and/or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.
A Hierarchy of Controls seems to be common - the user should investigate:
- Reduction
- Reuse
- Recycling
- Disposal (if all else fails)
This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.
DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.
- Recycle wherever possible.
- Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.
- Dispose of by: Burial in a licensed land-fill or Incineration in a licensed apparatus (after admixture with suitable combustible material)
- Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.

Section 14 - TRANSPORTATION INFORMATION

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: DOT, IATA, IMDG

Section 15 - REGULATORY INFORMATION

REGULATIONS
No data for cisatracurium besylate (CAS: 96946-42-8)

Section 16 - OTHER INFORMATION

LIMITED EVIDENCE
- Ingestion may produce health damage*.
- Cumulative effects may result following exposure*.
- Possible skin sensitizer*.
  * (limited evidence).

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use.
For additional technical information please call our toxicology department on +800 CHEMCALL.
Classification of the mixture and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.
A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.
The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: May-14-2009
Print Date: Jul-20-2010